FIELD: medicine, pharmacy. SUBSTANCE: invention proposes the drug that is the composition showing synergistic, biological, neurometabolic and providing cellular trophism and also etiopathogenic and homeostatic effects. Composition is developed on the basis of combination the following active components: (a) with respect to oxidative and catabolic stress: methionine with aminoethanolphenoxy acetates and/or aminoethylphenoxy acetamides; (b) with respect to anabolic stress: hydrooxopyrimidine carboxylates and/or oxopyrrolidine acetamides with potassium, zinc or lithium; (c) vasodilating and lipidemia normalizing preparations: nicotinic alcohol and/or acid or their derivatives with magnesium and iodine; (d) energy activating and (e) antitoxic compounds: aspartate, fructose, vitamin B1, vitamin B6, hydroorthophosphate and sulfate. Method of preparing the drug involves the following stages: (a) pharmaceutical preparing two complementary types of capsules or tablets with cover that are soluble in stomach and intestine being the latter have enterosoluble envelope; (b) prolonged release of vasodilating preparation from intestine-soluble standard dose. Invention provides emotional-affective stabilization and maintenance of human mental functions under stress conditions. EFFECT: improved method of preparing, enhanced effectiveness of drug. 7 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
PREPARATION AND METHOD FOR BIOGENIC BODY STIMULATION | 2002 |
|
RU2216346C1 |
METHOD FOR PREVENTING AND TREATING CHRONIC FATIGUE SYNDROME | 2015 |
|
RU2589694C1 |
PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF MENOPAUSE OSTEOPOROSIS IN WOMEN | 2007 |
|
RU2379043C2 |
BIOLOGIALLY ACTIVE AGENT HAVING EFFECT ON GENERAL METABOLIC, EXCITATORY AND INHIBITORY NERVE FUNCTION AND INTELLECTUAL MNESTIC CEREBRAL FUNCTIONS (VERSIONS) | 2011 |
|
RU2461374C1 |
COMBINATION IN ORAL DISPERSIBLE FORM WITH THERAPEUTIC ACTION ON ACTIVATING AND INHIBITORY FUNCTIONS OF NERVOUS SYSTEM (VERSIONS) | 2011 |
|
RU2464013C1 |
ENANTIOMERS OF (+)-AND(-)-TRANS-2,3,4,4a,5,9b-HEXAHYDRO-2,8-DIMETHYL-1H-PYRIDO[4,3- b]INDOL | 2005 |
|
RU2330852C1 |
INJECTION FORM OF PHARMACEUTICAL COMPOSITION (VERSIONS) FOR PREVENTING AND TREATING NEUROPATHIES AND METHOD FOR PREPARING IT | 2010 |
|
RU2448706C2 |
SYGETHIN-BASED PHARMACEUTICAL STRUCTURE FOR OSTEOPOROSIS PREVENTION AND TREATMENT (VERSIONS) | 2007 |
|
RU2356546C1 |
METABOLIC CORRECTION METHOD IN PATIENTS WITH PROTEIN-ENERGY INSUFFICIENCY (PEI) | 2019 |
|
RU2714315C1 |
COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL OR MENTAL DISORDERS, CONTAINING EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS PARACASEI | 2021 |
|
RU2819806C1 |
Authors
Dates
2000-07-20—Published
1994-06-02—Filed